Investors are evaluating the potential of two finance companies, Advanced Medical Isotope and SLR Investment, to determine which offers a more attractive opportunity. This comparison examines various factors including risk, valuation, institutional ownership, analyst recommendations, dividends, earnings, and profitability.
Valuation and Earnings Overview
Both companies display distinct financial profiles. SLR Investment, trading on NASDAQ under the ticker SLRC, has a consensus price target of $16.04, suggesting a potential upside of 7.91%. In contrast, Advanced Medical Isotope, listed on OTCMKTS as RDGL, has not seen similar analyst enthusiasm. The differences in projected performance indicate that analysts view SLR Investment as the more favorable option.
Institutional and Insider Ownership
A key indicator of investor confidence is the level of institutional ownership. Currently, 35.3% of SLR Investment shares are held by institutional investors, indicating strong support from endowments and hedge funds. Conversely, 18.5% of Advanced Medical Isotope shares are owned by insiders, while just 8.8% of SLR Investment shares are in the hands of insiders. This disparity suggests that SLR Investment enjoys a higher level of institutional trust.
In terms of profitability, the financial metrics of both companies reveal significant contrasts. Advanced Medical Isotope operates with a beta of -0.56, indicating that its share price is 156% less volatile than the S&P 500. In comparison, SLR Investment has a beta of 0.7, suggesting that its stock is 30% less volatile than the benchmark. This lower volatility might appeal to risk-averse investors.
Company Profiles
Advanced Medical Isotope, which changed its name to Vivos Inc. in December 2017, is based in Richland, Washington. The company develops radiation oncology medical devices, specifically brachytherapy devices for treating non-resectable tumors. Its products include the yttrium-90 based RadioGel and IsoPet, designed for both human and veterinary applications.
On the other hand, SLR Investment Corp. specializes in a broad range of financial services, focusing on secured debt, subordinated debt, and equity investments in leveraged middle-market companies. The fund’s investment strategy spans multiple sectors, including aerospace, automotive, healthcare, and technology, with typical investments ranging between $5 million and $100 million. It targets companies with revenues between $50 million and $1 billion.
Analysts favor SLR Investment over Advanced Medical Isotope for numerous reasons, including its stronger consensus rating, higher anticipated upside, and robust institutional support. With substantial differences in financial stability and growth prospects, investors may find SLR Investment to be the more compelling choice in the current financial landscape.
